eFFECTOR Therapeutics Investor Event: Zotatifin in ER+ Metastatic Breast Cancer
About The Event
Join us for a virtual investor event with eFFECTOR Therapeutics, featuring clinical expert Dr. Sarat Chandarlapaty of Memorial Sloan Kettering Cancer Center, discussing the unmet medical need and current treatment landscape for patients with ER+ Metastatic Breast Cancer.
The event will highlight data from Phase 2 expansion cohorts evaluating zotatifin, a potent and highly selective elF4A RNA helicase inhibitor, in patients with ER+ Metastatic Breast Cancer, being presented at the ASCO 2023 Annual Meeting.
A live question and answer session will follow the formal presentations.